• Natera reported new Signatera clinical data already presented at the ASTRO 2026 annual meeting, its first appearance at the conference.
• Across multiple studies, Signatera monitoring flagged patients at higher risk of relapse following chemoradiation or radiotherapy, supporting earlier intervention decisions.
• Data also supported use in organ-preservation strategies by helping identify patients more likely to remain disease-free under surveillance.
• Results were shown in colorectal and anal cancers, with additional evidence in gynecologic settings, broadening the test’s potential footprint in radiation oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006758428) on October 06, 2026, and is solely responsible for the information contained therein.